Therapeutic radionuclides include those emitting alpha particles, beta particles, or Auger electrons. Among them, alpha particles are characterized by high energy, strong focusing, short range, significant radiobiological effects, and potent cytotoxicity. After precise targeting of tumors, alpha radionuclides can release their enormous energy within the region of minimal residual disease, efficiently killing tumor cells while minimizing ionizing radiation damage to surrounding normal tissues and organs.   

²¹¹At is the most promising alpha-emitting radionuclide for targeted therapy, and its application serves as the cornerstone and distinguishing feature of our technology platform.   

•   Clear Decay Chain   

As an alpha emitter, ²¹¹At significantly improves therapeutic efficacy while reducing patients   whole-body radiation dose and enhancing treatment safety— a distinct advantage over other alpha radionuclides (e.g., ²²⁵Ac, ²¹²Pb, etc.).

•   Optimal Half-Life   

With a half-life of 7.2 hours, ²¹¹At is well-suited for outpatient treatment, facilitating precision design of drug and clinical application.   

•   Ideal for Minimal Residual Disease   

Its physical properties make it highly promising for eradicating post-surgical residual lesions, preventing recurrence, and treating micrometastases.

•   Stable Supply Partnership   

InnovaRadi has established strategic cooperation with leading global ²¹¹At manufacturers to ensure the stable supply of high-quality ²¹¹At.